Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099679 | 1.00 | FKBP1A (0.59) | FKBP1A | |
| SCHEMBL6098871 | 0.91 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL6098874 | 0.91 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL6100689 | 0.88 | FKBP1A (0.72) | FKBP1A | |
| SCHEMBL6099159 | 0.87 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL5833657 | 0.84 | FKBP1A (0.83) | FKBP1A | |
| SCHEMBL4679872 | 0.83 | FKBP1A (0.74) | FKBP1A | |
| SCHEMBL6100156 | 0.83 | FKBP1A (0.74) | FKBP1A | |
| SCHEMBL6428074 | 0.77 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL6428204 | 0.77 | FKBP1A (0.71) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106652-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2004-06-03 | — | — | US | claimed |
| JP-2003514893-A | — | — | 2003-04-22 | — | — | JP | claimed |
| US-20020193420-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. (US) | 2002-12-19 | — | — | US | claimed |
| EP-1233945-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL Holdings, Inc. (US) | 2002-08-28 | — | — | EP | claimed |
| US-20010056103-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2001-12-27 | — | — | US | claimed |
| WO-2001038304-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL HOLDINGS, INC. (US) | 2001-05-31 | — | — | WO | claimed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | claimed |
| US-6984639-B2 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050148637-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2005-07-07 | — | — | US | disclosed |
| US-20040106652-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-20020193420-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. (US) | 2002-12-19 | — | — | US | disclosed |
| EP-1233945-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL Holdings, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6417209-B2 | NON-IMMUNOSUPPRESSIVE, PIPERIDINO OR PYRROLIDINO AMIDE DERIVATIVE HAS AN AFFINITY FOR AN FKBP-TYPE IMMUNOPHILIN, USEFUL FOR TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS | GPI NIL HOLDINGS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20010056103-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001038304-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL HOLDINGS, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056103-A1 | Heterocyclic ketone and thioester compounds and uses | BDNF, NTRK2, NTRK1 | FKBP1A 955/4885 |
| US-20050148637-A1 | Heterocyclic ketone and thioester compounds and uses | BDNF, NTRK2, NTRK1 | FKBP1A 955/4885 |
| US-20040106652-A1 | Heterocyclic ketone and thioester compounds and uses | BDNF, NTRK2, NTRK1 | FKBP1A 955/4885 |
| US-20020193420-A1 | Heterocyclic ketone and thioester compounds and uses | BDNF, NTRK2, NTRK1 | FKBP1A 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.